¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"monoclonal peak"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 12 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • monoclonal
    ´Ü¼¼Æ÷±º-, ´ÜŬ·Ð-
  • monoclonal antibody
    ´ÜŬ·ÐÇ×ü
  • monoclonal gammopathy
    ´Ü¼¼Æ÷±º°¨¸¶±Û·ÎºÒ¸°º´Áõ
  • peak
    ÃÖ°íÁ¡, ÃÖ´ë
  • peak concentration time
    ÃÖ°í³óµµ½Ã°£
  • peak expiratory flow
    Ãִ볯¼ûÀ¯·®
  • peak expiratory flow rate
    ÃÖ°í³¯¼ûÀ¯¼Ó, ÃÖ°íÈ£±âÀ¯¼Ó
  • peak flow meter
    ÃÖ´ëÀ¯·®°è, ÃÖ°íÀ¯·®°è
  • peak flow rate
    1. ÃÖ°íÀ¯¼Ó 2. ÃÖ°í¿äÈ帧¼Óµµ 3. ÃÖ´ëÀ¯·®
  • peak level
    ÃÖ°íÄ¡
  • peak metabolism
    ÃÖ´ë´ë»ç
  • sensory peak latency
    °¨°¢½Å°æÁ¤Á¡Àá½Ã
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • peak level
    ÃÖ°íÄ¡
  • peak
    ÃÖ°íÁ¡
  • peak expiratory flow rate
    ÃÖ°í³¯¼û¼Óµµ, ÃÖ°íÈ£±âÀ¯¼Ó
  • peak growth velocity
    Ãִ뼺Àå¼Óµµ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • monoclonal antibody
    ´ÜŬ·ÐÇ×ü
  • monoclonal immunoglobulin detection
    ´ÜÀÏŬ·Ð¸é¿ª±Û·ÎºÒ¸°°ËÃâ
  • monoclonal gammopathy
    ´Ü¼¼Æ÷±º°¨¸¶±Û·ÎºÒ¸°º´Áõ
  • monoclonal hypothesis
    ´ÜÀÏŬ·Ð°¡¼³
  • monoclonal
    ´Ü¼¼Æ÷±º-, Çѹ«¸®-
  • peak expiratory flow
    Ãִ볯¼ûÀ¯·®
  • peak level
    ÃÖ°íÄ¡
  • sensory peak latency
    °¨°¢½Å°æÁ¤Á¡Àá½Ã
  • peak metabolism
    ÃÖ´ë´ë»ç
  • peak flow meter
    ÃÖ´ëÀ¯·®°è, ÃÖ°íÀ¯·®°è
  • peak
    ÃÖ°íÁ¡
  • peak concentration time
    ÃÖ°í³óµµ½Ã°£
  • peak expiratory flow rate
    ÃÖ°í³¯¼û·ù·®
  • peak flow rate
    ÃÖ°íÀ¯¼Ó, ÃÖ°í±â·ù·®
  • peak gradient strength
    ÃÖ°í°æ»ç¼¼±â, ÃÖ°í±â¿ï±â¼¼±â
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • antibody, monoclonal
    ´Ü¼¼Æ÷±ºÇ×ü, Çѹ«¸®Ç×ü
  • antibody,monoclonal
    ´ÜŬ·Ð¼º(Ó¤¡­àõ)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • peak
    ÃÖ°íÁ¡
  • peak
    ÃÖ°íÁ¡(õÌÍÔïÇ), Á¤(ð¢).
  • peak absorbed dose
    ÃÖ´ëÈí¼ö¼±·®
  • peak concentration
    ÃÖ°í³óµµ(¡­ÒØöô).
  • peak concentration time
    ÃÖ°í³óµµ½Ã°£(õÌÍÔÒØöôãÁÊà).
  • peak expiratory flow
    ÃÖ´ëÈ£±âÀ¯·®.
  • peak expiratory flow rate
    ÃÖ°íÈ£±âÀ¯·®(õÌÍÔû¼Ñ¨êüåÖ).
  • peak flow meter
    ÃÖ´ëÀ¯·®°è, ÃÖ°íÀ¯·®°è (¡­êüåÖͪ).
  • peak flow rate
    ÃÖ´ëÀ¯¼Ó, ÃÖ°íÀ¯¼Ó(õÌÍÔ êüáÜ).
  • peak gradient strength
    ÃÖ°í °æ»ç ¼¼±â
  • peak intensity
    ÃÖ°í °­µµ (õÌÍÔ Ë­Óø), ÃÖ°í (õÌÍÔ) ¼¼±â
  • peak intensity
    ÃÖ°í °­µµ, ÃÖ°í ¼¼±â
  • peak level
    ÃÖ°í³óµµ
  • peak metabolism
    Á¤´ë»ç(ð¢ÓÛÞó).
  • peak power
    ÃÖ´ë·Â(õÌÓÞæ³).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • air peak
    °ø±âÁ¤Á¡ (ÍöѨð¢ïÇ)
  • monoclonal antibodies
    ´Ü(Ó¤)Ŭ·Ð Ç×ü(ù÷ô÷)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • monoclonal
    ´ÜÀÏŬ·Ð¼º, ´ÜÀϼ¼Æ÷±ºÀÇ
  • peak
    ÃÖ°íÁ¡, Á¤
  • peak gradient strength
    ÃÖ°í°æ»ç¼¼±â
  • peak intensity
    ÃÖ°í°­µµ, ÃÖ°í¼¼±â
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
JVP [POMD P 49 - 52]
  1) Jugular Vein Pressure
  2) Jugular Venous Pulse
...
PIP paralytic infantile paralysis; peak inflation pressure, peak inspiratory pressure; periodic interim ...
PPT parietal pleural tissue; partial prothrombin time; peak-to-peak threshold; Pfeiffer-Palm-Teller [syn...
MAbs Monoclonal Antibodies
MG   1) Myasthenia Gravis
  2) MonoGlyceride
  3) Monoclonal Gammop...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
peak VO2 Peak oxygen consumption
peak VO(2) Peak oxygen uptake
P-P peak to peak
BMG benign monoclonal gammopathy
Bi-MAbs Bispecific monoclonal antibodies
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • monoclonal
    ´ÜºÐÁö¼º, ´ÜÀÏ Å¬·Ð¼º, ´ÜÀÏ ¼¼Æ÷¼º, ´ÜŬ·Ð¼º, ´ÜÀÏ ¼¼Æ÷±ºÀÇ
    ´ÜÀÏ ¼¼Æ÷¿¡¼­ À¯·¡µÈ.
  • monoclonal gammopathy
    ´Ü Ŭ·Ð °¨¸¶º´Áõ, ´ÜÀÏ Å¬·Ð °¨¸¶º´Áõ
  • monoclonal immunoglobulin detection
    ´ÜÀÏ Å¬·Ð ¸é¿ª ±Û·ÎºÒ¸° °ËÃâ
  • monoclonal theory
    ´ÜÀÏ ¼¼Æ÷ À¯·¡¼³
  • DNA absorption peak
    ÃÖ°í DNA Èí¼ö
  • peak
    Á¤Á¡, ÃÖ°íÁ¡, Á¤
  • peak expiratory flow
    ÃÖ´ë È£±â À¯·®
  • peak flow rate
    ÃÖ´ë À¯¼Ó, ÃÖ°í À¯¼Ó
  • peak height velocity
    ½ÅÀåÀÇ ÃÖ´ë Áõ°¡, ÃÖ´ë Áõ°¡·® °î¼±
  • peak metabolism
    Á¤´ë»ç
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
monoclonal peak A narrow band visible on electrophoresis or an abnormal arc seen on immunoelectrophoresis, thought to represent immunoglobulin of one cell clone.
(05 Mar 2000)
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
antibodies, monoclonal Antibodies produced by clones of cells such as those isolated after hybridization of activated b lymphocytes with neoplastic cells. These hybrids are often referred to as hybridomas.
(12 Dec 1998)
monoclonal 1. <cell biology> Used of a cell line whether within the body or in culture to indicate that it has a single clonal origin.
2. <immunology> Monoclonal antibodies are produced by a single clone of hybridoma cells and are therefore a single species of antibody molecule.
(18 Nov 1997)
monoclonal antibodies Identical antibodies that are made in large amounts in the laboratory. Doctors are studying ways of using monoclonal antibodies to treat leukaemia.
(12 Dec 1998)
monoclonal antibody <immunology, molecular biology> A substance, usually a protein, which can be synthsised in the laboratory in pure form by a single clone (population) of cells.
These antibodies can be made in large quantities and have a specific affinity for certain target molecules called antigens which can be found on the surface of cells and those that are malignant.
Monoclonal antibodies are currently being investigated as a possible form of cancer treatment although their benefit has not be fully proven.
(16 Dec 1997)
monoclonal gammopathies, benign Conditions characterised by the presence of a monoclonal serum (or urine) protein without clinical manifestations of plasma cell dyscrasia.
(12 Dec 1998)
monoclonal immunoglobulin A homogenous immunoglobulin resulting from the proliferation of a single clone of plasma cells and which, during electrophoresis of serum, appears as a narrow band or "spike"; it is characterised by heavy chains of a single class and subclass, and light chains of a single type.
Synonym: M protein, monoclonal protein, paraprotein.
(05 Mar 2000)
monoclonal protein A homogenous immunoglobulin resulting from the proliferation of a single clone of plasma cells and which, during electrophoresis of serum, appears as a narrow band or "spike"; it is characterised by heavy chains of a single class and subclass, and light chains of a single type.
Synonym: M protein, monoclonal protein, paraprotein.
(05 Mar 2000)
biclonal peak Two narrow electrophoretic bands thought to represent immunoglobulin of two cell lines.
(05 Mar 2000)
peak The top or upper limit of a graphic tracing or of any variable.
Origin: M.E. Peke, pike, fr. Sp. Pico, beak, fr. L. Picus, magpie
(05 Mar 2000)
peak expiratory flow The maximum flow at the outset of forced expiration, which is reduced in proportion to the severity of airway obstruction, as in asthma.
(05 Mar 2000)
peak expiratory flow rate Measurement of the maximum rate of airflow attained during a forced vital capacity determination. Common abbreviations are pefr and pfr.
(12 Dec 1998)
peak flow <chest medicine, physiology> The maximum flow rate of air breathed out during forced expiration.
(15 Nov 1997)
peak flow rate Maximum urinary flow rate during voiding as measured by a uroflowmeter.
(05 Mar 2000)
peak magnitude The greatest amplitude.
(05 Mar 2000)
peak plasma drug concentration <pharmacology> The highest level of drug that can be obtained in the blood usually following multiple doses.
(09 Oct 1997)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • monoclonal
    ´ÜÀÏ ¼¼Æ÷¿¡¼­ À¯·¡ÇÏ´Â ¼¼Æ÷ÀÎ(·Î ¸¸µé¾î Áö´Â)
  • monoclonal antibody
    ´ÜÀÏ Å¬·Ð Ç×ü
  • peak
    ÷´Ü
  • peak
    ºÀ¿ì¸®;»ê²À´ë±â;÷´Ü;ÃÖ°íÁ¡;ì;»ÏÁ·ÇÑ
  • peak experience
    Áö°í üÇè;°è½Ã
  • peak fresh
    Á¦Ã¶ÀÇ;ÇÑâ¶§ÀÇ
  • peak hour
    ÃÖ°í½Ã;°ñµç ¾Æ¿ö
  • peak load
    ÇDZ×(ÀýÁ¤)ºÎÇÏ;ÀýÁ¤ ÇÏÁß
  • widow's peak
    À̸¶ Áß¾Ó¿¡ vÀÚÇüÀ¸·Î ³­ ¸Ó¸®
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á